650
Participants
Start Date
September 20, 2017
Primary Completion Date
December 23, 2022
Study Completion Date
August 31, 2028
Darbepoetin
Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
Placebo
normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
University of Rochester, Rochester
Univeristy of Pennsylvania, Philadelphia
RTI International, Durham
Duke University, Durham
Emory University, Atlanta
University of Alabama at Birmingham, Birmingham
Research Institute at Nationwide Children's Hospital, Columbus
Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland
Cincinnati Children's Medical Center, Cincinnati
University of Iowa, Iowa City
University of Texas Southwestern Medical Center at Dallas, Dallas
University of Texas Health Science Center at Houston, Houston
University of Utah, Salt Lake City
University of New Mexico, Albuquerque
Stanford University, Palo Alto
Brown University - Women and Infants Hospital of Rhode Island, Providence
National Heart, Lung, and Blood Institute (NHLBI)
NIH
NICHD Neonatal Research Network
NETWORK